Second Sight Medical Products Inc (NASDAQ:EYES) rose 6% during trading on Monday . The stock traded as high as $0.80 and last traded at $0.79. Approximately 176,113 shares were traded during mid-day trading, a decline of 65% from the average daily volume of 507,648 shares. The stock had previously closed at $0.75.
Separately, Zacks Investment Research lowered Second Sight Medical Products from a “buy” rating to a “hold” rating in a research note on Thursday, June 4th.
The business’s 50 day simple moving average is $0.85 and its 200-day simple moving average is $1.41. The stock has a market capitalization of $19.75 million, a P/E ratio of -0.45 and a beta of 2.19.
Second Sight Medical Products (NASDAQ:EYES) last posted its quarterly earnings results on Thursday, August 13th. The medical device company reported ($0.15) earnings per share (EPS) for the quarter. Second Sight Medical Products had a negative return on equity of 470.66% and a negative net margin of 994.14%.
A hedge fund recently bought a new stake in Second Sight Medical Products stock. Virtu Financial LLC acquired a new position in shares of Second Sight Medical Products Inc (NASDAQ:EYES) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 54,087 shares of the medical device company’s stock, valued at approximately $53,000. Virtu Financial LLC owned 0.23% of Second Sight Medical Products at the end of the most recent quarter. Hedge funds and other institutional investors own 3.63% of the company’s stock.
About Second Sight Medical Products (NASDAQ:EYES)
Second Sight Medical Products, Inc develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury.
Read More: Dow Jones Industrial Average (DJIA)
Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.